Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity?

On July 30, Keros Therapeutics (KROS) reached a $20 million development milestone payment from partner Takeda Pharmaceutical Company Limited (TAK) after the first patient was dosed in the Phase 3 ELRiSE MDS clinical trial. This payout was part of their January 2025 global licensing agreement, which also granted Keros a $200 million upfront payment and potential future milestones totaling over $1.1 billion in cash and royalties. Keros plans to distribute 25% of the net cash proceeds from this milestone to its shareholders.

Comparing Keros Therapeutics' Q2 2026 results against Takeda's Q1 FY2026 performance, Keros reported $0 in total revenue and a net loss of $28.7 million ($1.45 per share), while Takeda reported revenue of JPY 1.22 trillion (~$7.5 billion) and a core EPS of JPY 154 billion. However, Keros' financial situation is bolstered by $257.6 million in cash and equivalents, providing a clean runway through the first half of 2028.

Takeda's financial strength lies in its massive commercial scale, core EPS, and high-margin portfolio. However, Keros Therapeutics is executing well for a clinical-stage firm by leveraging Takeda's resources to offset R&D costs, maintain a zero debt burden, and return capital to shareholders. The primary upside for Keros centers on successful Phase 3 trials of its lead candidate elritercept, which could unlock over $1.1 billion in future milestones and high-margin royalties.

The main risk for Keros is its reliance on a single clinical candidate and its complete dependence on Takeda for commercial execution outside China.